Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-07 · accession 0000950170-25-002973 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-07 | 2025-01-07 | NAMS | Somaiya Mayur Ian | CFO | A - Grant | — | +38.0K | 38.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-01-07 | A | A | 38,000 | — | 38,000 | D | — | — | (F1) Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. (F2) Each RSU was granted on January 7, 2025 for no consideration. |